Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2005
11/10/2005WO2005087210A3 Prevention of retinopathy by inhibition of the visual cycle
11/10/2005WO2005084365A3 Triptolide lactone ring derivatives as immunomodulators and anticancer agents
11/10/2005WO2005083086A3 Epha4 as therapeutic target of prc and pdaca
11/10/2005WO2005082858A3 Isoquinoline derivatives
11/10/2005WO2005082457A3 Use of substituted 1,2,3 indolizine derivatives for treating diseases associated with a pathological choroidal angiogenesis
11/10/2005WO2005082397B1 Combinatorial therapies for the treatment of neoplasias using the opioid growth factor receptor
11/10/2005WO2005082359A3 Use of beta-lapachone for the treatment of pancreatic cancer
11/10/2005WO2005082355A3 Use of beta-lapachone for treatment of colon cancer
11/10/2005WO2005079795A3 Dpp-iv inhibitors for treating neurodegeneration and cognitive disorders
11/10/2005WO2005077385A3 Methods for treating resistant or refractory tumors
11/10/2005WO2005077360A3 Topical treatment of otitis externa with antifungals or antibacterials
11/10/2005WO2005075684A3 Use of organic anion transporter b in screens for candidate substrates for crossing the blood brain barrier
11/10/2005WO2005070412A3 Method of using punicic acid to enhance immune response and prevent metabolic disorders
11/10/2005WO2005067908A3 Memantine for the treatment of mild and mild-to-moderate alzheimer’s disease
11/10/2005WO2005067564A3 6-11 bicyclic erythromycin derivatives
11/10/2005WO2005067548A3 Use of ribose in recovery from anaesthesia
11/10/2005WO2005063281A3 Means for inhibiting viral replication by regulation of protein folding
11/10/2005WO2005062718A3 Methods of administering 3,3,14,14 tetramethyl hexadecane 1,16 dioic acid
11/10/2005WO2005058298A3 Fk228 analogs and their use as hdac-inhibitors
11/10/2005WO2005051456A3 Composition and apparatus for transdermal delivery
11/10/2005WO2005049000A3 Treatment of phenylketonurias with bh4
11/10/2005WO2005047304A3 Method for obtaining natural products from plant material
11/10/2005WO2005046797A3 Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
11/10/2005WO2005042509A8 7-`(7-alkoxy)-chrom-3-en-6-yl!-heptatrienoic acid and 7-`(3­alkoxy)-5,6-dihydronaphthalen-2-yl!-heptatrienoic acid derivatives modulators
11/10/2005WO2005041924A3 Administration of levodopa and carbidopa
11/10/2005WO2005037256A3 Liquid preparation containing tobramycin
11/10/2005WO2005034846A3 Withanamide and withanolide compositions and method of use thereof
11/10/2005WO2005032465A3 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
11/10/2005WO2005030121A3 Compounds, compositions and methods
11/10/2005WO2005023328A3 Methods for intradermal delivery of therapeutics agents
11/10/2005WO2005022116A9 Antioxodant sensor, methods and compositions
11/10/2005WO2005018544A8 Therapy-enhancing glucan
11/10/2005WO2005016319A3 Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
11/10/2005WO2005016231A3 Agents and methods for treatment of disease by oligosaccharide targeting agents
11/10/2005WO2005007600A3 Novel methods using aminobenzoic acid compounds
11/10/2005WO2005002672A3 Sirt1 modulators for manipulating cells/organism lifespan/stress response
11/10/2005WO2005000216A3 Combination of an nmda receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders
11/10/2005WO2004112725A3 Methods for inhibiting or reversing tau filament fibrillization
11/10/2005WO2004103284A3 Compositions of a benzenesulfonamide or methylsulfonylbenzene cyclooxygenase-2 selective inhibitor and a cholinergic agent for the treatment of reduced blood flow or trauma to the central nervous system
11/10/2005WO2004099155A3 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (phenyl) amide derivates and related compounds as bradykinin b1 receptor antagonists for the treatment of inflamatory diseases
11/10/2005WO2004091666A8 Compositions containing piperacillin and tazobactam useful for injection
11/10/2005WO2004090691A3 Method and apparatus for system management using codebook correlation with symptom exclusion
11/10/2005WO2004087121A8 Water soluble formulations of digitalis glycosides for treating cell-proliferative and other diseases
11/10/2005WO2004082634A3 Facially amphiphilic polymers and oligomers and uses thereof
11/10/2005WO2004080417A3 Methods and compositions for blocking the calcium cascade
11/10/2005WO2004071428A3 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure
11/10/2005WO2004069142A8 Anti-candida agents for the treatment of prion diseases
11/10/2005WO2004062607A3 Use of weak acids or their precursors for the treatment of tuberculosis (tb) and drug resistant tb
11/10/2005WO2003101176A8 Method, composition and kit for antigenic binding of norwalk-like viruses
11/10/2005WO2001009093A8 Benzenamine derivatives as anti-coagulants
11/10/2005US20050251871 Novel ubiquitin ligases as therapeutic targets
11/10/2005US20050251289 Medicament dispenser
11/10/2005US20050251246 Dilating and support apparatus with disease inhibitors and methods for use
11/10/2005US20050251231 Treatment method and apparatus for basal cell carcinoma
11/10/2005US20050251149 Bone substitute compositions and method of use
11/10/2005US20050250970 Zeolite Y alkylation catalysts
11/10/2005US20050250950 1,3-oxathiolane nucleoside analogues
11/10/2005US20050250946 Method for the synthesis of 2',3'-dideoxy-2',3'-didehydronucleosides
11/10/2005US20050250939 Process for the production of multiple cross-linked hyaluronic acid derivatives
11/10/2005US20050250855 Compounds for treating human papillomavirus
11/10/2005US20050250854 Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
11/10/2005US20050250853 Beta-tubulin inhibitors
11/10/2005US20050250852 For facilitating the delivery of active agents, such as insulin, to a target
11/10/2005US20050250851 Methods for treating neuropsychiatric disorders
11/10/2005US20050250850 Amino acid composition promoting collagen synthesis
11/10/2005US20050250849 Basic amino acid - methionine hydroxy analog compositions
11/10/2005US20050250848 Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers
11/10/2005US20050250847 Use of a dicarbamate enantiomer substantially free of other enantiomers or an enantiomeric mixture wherein a monocarbamate enantiomer predominates in preventing or treating neuropathic pain
11/10/2005US20050250846 Non-peptide GnRH agents, pharmaceutical compositions and methods for their use
11/10/2005US20050250845 Pseudopolymorphic forms of a hiv protease inhibitor
11/10/2005US20050250844 Methods of treating cancer using C-4 carbonate taxanes
11/10/2005US20050250843 synergistic antihypoxic mixture: acetylcholine esterase inhibitor (Donepezil and Tacrine) and neuroprotectant 1-[3-(2-(1-benzothiophen-5-yl)ethoxy)propyl]-3-azetidinol maleate; dysfunction of cerebral acetylcholine neurons in sequelae of cerebrovascular and senile dementia, Alzheimer's disease
11/10/2005US20050250841 Autoinducer molecule
11/10/2005US20050250840 treating, or lessening the severity of, diabetic nephropathy in an adult human patient in need thereof by administering to patient 500 mg mycophenolate mofetil and 5 mg lisinopril
11/10/2005US20050250839 Indoleacetic acid and indenacetic acid derivatives as therapeutic agents with reduced gastrointestinal toxicity
11/10/2005US20050250838 Formulation for sustained delivery
11/10/2005US20050250837 Use of C-Raf inhibitors for the treatment of neurodegenerative diseases
11/10/2005US20050250836 Inhibitors of checkpoint kinases (Wee1 and Chk1)
11/10/2005US20050250835 Novel tumor-selective chemotherapeutic agents
11/10/2005US20050250834 11-(Aminoalkyl)isoindolo[2,1-a]indol-6-ones: 11-(2-Dimethylaminoethyl)-2-fluoroisoindolo[2,1-a]indol-6-one; psychological disorders, drug abuse, sleep disorders, Alzheimer's, Parkinson's and Huntington's disease, Irritable bowel syndrome, chemotherapy induced emesis, spinal trauma and/or head injury
11/10/2005US20050250833 Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
11/10/2005US20050250832 For increasing blood-brain barrier permeability
11/10/2005US20050250831 Peroxisome proliferator activated receptor modulators
11/10/2005US20050250830 Substituted amine radical as building blocks; increases structural diversity
11/10/2005US20050250829 Kinase inhibitors
11/10/2005US20050250828 slurrying, precipitating, filtering
11/10/2005US20050250827 Preparation of candesartan cilexetil in high purity
11/10/2005US20050250826 Compounds, compositions, processes of making, and methods of use related to inhibiting macrophage migration inhibitory factor
11/10/2005US20050250825 peroxisome proliferator activated receptor modulators; diabetes mellitus; side effects reduction; 2-Methyl-2-{4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenoxy}propionic acid; Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, atherosclerosis
11/10/2005US20050250824 Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient
11/10/2005US20050250821 Quaternary ammonium compounds in the treatment of water and as antimicrobial wash
11/10/2005US20050250820 Therapeutic modulation of PPARgamma activity
11/10/2005US20050250819 Inhibitors of bacterial type III protein secretion systems
11/10/2005US20050250818 Ortho substituted aryl or heteroaryl amide compounds
11/10/2005US20050250817 Pharmaceutical compositions of lipase-containing products, in particular of pancreation
11/10/2005US20050250815 e.g. 4-Methoxy-pyrrolidine-1,2-dicarboxylic acid 1-[(4-chloro-phenyl)-amide] 2-{[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenyl]-amide}; anticoagulant, thrombolytic agent; thrombus formation within blood vessels; cardiovascular disease
11/10/2005US20050250814 Piperidinyl-alpha-aminoamide modulators of chemokine receptor activity
11/10/2005US20050250813 Injectable depot formulation comprising crystals of iloperidone
11/10/2005US20050250812 Methods for treating lewy body dementia
11/10/2005US20050250811 Such as 14-O-[4-hydroxy-N-valyl-piperidin-3-yl]-sulfanylacetylmutilin
1 ... 4472 4473 4474 4475 4476 4477 4478 4479 4480 4481 4482 4483 4484 4485 4486 4487 4488 4489 4490 4491 4492 ... 7860